Video

The Future of Pharmacy, The Ability to Move Beyond Dispensing for Pharmacists

We need to be able to build on that momentum, and at the same time, we need sustainable reimbursement models.

Crystal Lennartz, VP, General Manager of Health Mart Atlas, spoke to Pharmacy Times about her session at McKesson ideaShare 2022, titled "Pharmacy Beyond the Pill: Clinical Payment Services and Reimbursement."

Crystal Lennartz: I couldn't be more excited about the future of pharmacy and really the ability to move beyond dispensing to additional services for pharmacists. I think what happened with COVID with immunizations, as well as now more recently with Paxlovid and the ability for pharmacists to prescribe—we need to be able to build on that momentum, and at the same time we need sustainable reimbursement models. So, when those 2 things come together, I think it's really going to unleash the power of community and the impact that pharmacists can have.

Related Videos
Image Credit: © Birdland - stock.adobe.com
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC